{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T12:54:45Z","timestamp":1780491285025,"version":"3.54.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003136","name":"Edmond J. Safra Philanthropic Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003136","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["112927078 - TRR 83"],"award-info":[{"award-number":["112927078 - TRR 83"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008361","name":"Scleroseforeningen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008361","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["204290\/Z\/16\/Z"],"award-info":[{"award-number":["204290\/Z\/16\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Mixed lineage kinase domain-like (MLKL) is the main executor of necroptosis, an inflammatory form of programmed cell death. Necroptosis is implicated in combating infections, but also in contributing to numerous other clinical conditions, including cardiovascular diseases and neurodegenerative disorders. Inhibition of necroptosis is therefore of therapeutic interest. Here we report two siblings both of whom over the course of 35 years developed a similar progressive, neurodegenerative spectrum disorder characterized by paresis, ataxia and dysarthria. Magnetic resonance imaging of their central nervous system (CNS) revealed severe global cerebral volume loss and atrophy of the cerebellum and brainstem. These brothers are homozygous for a rare haplotype identified by whole genome sequencing carrying a frameshift variant in\n                    <jats:italic>MLKL<\/jats:italic>\n                    , as well as an in-frame deletion of one amino acid in the adjacent fatty acid 2-hydroxylase (\n                    <jats:italic>FA2H<\/jats:italic>\n                    ) gene. Functional studies of patient-derived primary cells demonstrated that the variant in\n                    <jats:italic>MLKL<\/jats:italic>\n                    leads to a deficiency of MLKL protein resulting in impairment of necroptosis. Conversely, shotgun lipidomic analysis of the variant in\n                    <jats:italic>FA2H<\/jats:italic>\n                    shows no impact on either the abundance or the enzymatic activity of the encoded hydroxylase. To our knowledge, this is the first report of complete necroptosis deficiency in humans. The findings may suggest that impaired necroptosis is a novel mechanism of neurodegeneration, promoting a disorder that shares some clinical features with primary progressive multiple sclerosis (PPMS) and other neurodegenerative diseases. Importantly, the necroptotic deficiency does not cause symptoms outside the nervous system, nor does it confer susceptibility to infections. Given the current interest in pharmacological inhibition of necroptosis by targeting MLKL and its associated pathways, this strategy should be developed with caution, with careful consideration of the possible development of adverse neurological effects.\n                  <\/jats:p>","DOI":"10.1038\/s41419-020-2494-0","type":"journal-article","created":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T08:03:27Z","timestamp":1588320207000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["A novel neurodegenerative spectrum disorder in patients with MLKL deficiency"],"prefix":"10.1038","volume":"11","author":[{"given":"Soren L.","family":"Faergeman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrine E.","family":"Attfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Desel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subita Balaram","family":"Kuttikkatte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette","family":"Sommerlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise Torp","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorgen","family":"Frokiaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel A.","family":"Friese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Luchtenborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Br\u00fcgger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette Bang","family":"Oturai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calliope A.","family":"Dendrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Fugger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,1]]},"reference":[{"key":"2494_CR1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.cell.2011.11.031","volume":"148","author":"L Sun","year":"2012","unstructured":"Sun, L. et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell 148, 213\u2013227 (2012).","journal-title":"Cell"},{"key":"2494_CR2","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1056\/NEJMra1310050","volume":"370","author":"A Linkermann","year":"2014","unstructured":"Linkermann, A. & Green, D. R. Necroptosis. N. Engl. J. Med. 370, 455\u2013465 (2014).","journal-title":"N. Engl. J. Med."},{"key":"2494_CR3","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.immuni.2013.06.018","volume":"39","author":"JM Murphy","year":"2013","unstructured":"Murphy, J. M. et al. The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism. Immunity 39, 443\u2013453 (2013).","journal-title":"Immunity"},{"key":"2494_CR4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/ncb2883","volume":"16","author":"Z Cai","year":"2014","unstructured":"Cai, Z. et al. Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis. Nat. Cell Biol. 16, 55\u201365 (2014).","journal-title":"Nat. Cell Biol."},{"key":"2494_CR5","doi-asserted-by":"publisher","first-page":"15072","DOI":"10.1073\/pnas.1408987111","volume":"111","author":"JM Hildebrand","year":"2014","unstructured":"Hildebrand, J. M. et al. Activation of the pseudokinase MLKL unleashes the four-helix bundle domain to induce membrane localization and necroptotic cell death. Proc. Natl Acad. Sci. USA 111, 15072\u201315077 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2494_CR6","doi-asserted-by":"publisher","first-page":"15438","DOI":"10.1073\/pnas.1412767111","volume":"111","author":"X Wang","year":"2014","unstructured":"Wang, X. et al. Direct activation of RIP3\/MLKL-dependent necrosis by herpes simplex virus 1 (HSV-1) protein ICP6 triggers host antiviral defense. Proc. Natl Acad. Sci. USA 111, 15438\u201315443 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2494_CR7","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.chom.2015.01.003","volume":"17","author":"H Guo","year":"2015","unstructured":"Guo, H. et al. Herpes simplex virus suppresses necroptosis in human cells. Cell Host Microbe 17, 243\u2013251 (2015).","journal-title":"Cell Host Microbe"},{"key":"2494_CR8","doi-asserted-by":"publisher","first-page":"11635","DOI":"10.1074\/jbc.M115.646042","volume":"290","author":"S Omoto","year":"2015","unstructured":"Omoto, S. et al. Suppression of RIP3-dependent necroptosis by human cytomegalovirus. J. Biol. Chem. 290, 11635\u201311648 (2015).","journal-title":"J. Biol. Chem."},{"key":"2494_CR9","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/ni.2397","volume":"13","author":"N Robinson","year":"2012","unstructured":"Robinson, N. et al. Type I interferon induces necroptosis in macrophages during infection with Salmonella enterica serovar Typhimurium. Nat. Immunol. 13, 954\u2013962 (2012).","journal-title":"Nat. Immunol."},{"key":"2494_CR10","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cell.2013.03.022","volume":"153","author":"FJ Roca","year":"2013","unstructured":"Roca, F. J. & Ramakrishnan, L. TNF dually mediates resistance and susceptibility to mycobacteria via mitochondrial reactive oxygen species. Cell 153, 521\u2013534 (2013).","journal-title":"Cell"},{"key":"2494_CR11","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1016\/j.celrep.2016.07.039","volume":"16","author":"K Kitur","year":"2016","unstructured":"Kitur, K. et al. Necroptosis promotes Staphylococcus aureus clearance by inhibiting excessive inflammatory signaling. Cell Rep. 16, 2219\u20132230 (2016).","journal-title":"Cell Rep."},{"key":"2494_CR12","doi-asserted-by":"publisher","first-page":"16258","DOI":"10.1038\/nmicrobiol.2016.258","volume":"2","author":"JS Pearson","year":"2017","unstructured":"Pearson, J. S. et al. EspL is a bacterial cysteine protease effector that cleaves RHIM proteins to block necroptosis and inflammation. Nat. Microbiol. 2, 16258 (2017).","journal-title":"Nat. Microbiol."},{"key":"2494_CR13","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1126\/science.aar2641","volume":"361","author":"D Cuchet-Lourenco","year":"2018","unstructured":"Cuchet-Lourenco, D. et al. Biallelic RIPK1 mutations in humans cause severe immunodeficiency, arthritis, and intestinal inflammation. Science 361, 810\u2013813 (2018).","journal-title":"Science"},{"key":"2494_CR14","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1073\/pnas.1813582116","volume":"116","author":"Y Li","year":"2019","unstructured":"Li, Y. et al. Human RIPK1 deficiency causes combined immunodeficiency and inflammatory bowel diseases. Proc. Natl Acad. Sci. USA 116, 970\u2013975 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2494_CR15","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1126\/science.aaf6803","volume":"353","author":"Y Ito","year":"2016","unstructured":"Ito, Y. et al. RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS. Science 353, 603\u2013608 (2016).","journal-title":"Science"},{"key":"2494_CR16","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1038\/nn.4608","volume":"20","author":"A Caccamo","year":"2017","unstructured":"Caccamo, A. et al. Necroptosis activation in Alzheimer\u2019s disease. Nat. Neurosci. 20, 1236\u20131246 (2017).","journal-title":"Nat. Neurosci."},{"key":"2494_CR17","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1016\/j.celrep.2015.02.051","volume":"10","author":"D Ofengeim","year":"2015","unstructured":"Ofengeim, D. et al. Activation of necroptosis in multiple sclerosis. Cell Rep. 10, 1836\u20131849 (2015).","journal-title":"Cell Rep."},{"key":"2494_CR18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41583-018-0093-1","volume":"20","author":"J Yuan","year":"2019","unstructured":"Yuan, J., Amin, P. & Ofengeim, D. Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases. Nat. Rev. Neurosci. 20, 19\u201333 (2019).","journal-title":"Nat. Rev. Neurosci."},{"key":"2494_CR19","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.immuni.2017.06.001","volume":"47","author":"S Yoon","year":"2017","unstructured":"Yoon, S., Kovalenko, A., Bogdanov, K. & Wallach, D. MLKL, the protein that mediates necroptosis, also regulates endosomal trafficking and extracellular vesicle generation. Immunity 47, 51\u201365 e57 (2017).","journal-title":"Immunity"},{"key":"2494_CR20","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.cell.2017.03.020","volume":"169","author":"YN Gong","year":"2017","unstructured":"Gong, Y. N. et al. ESCRT-III acts downstream of MLKL to regulate necroptotic cell death and its consequences. Cell 169, 286\u2013300 e216 (2017).","journal-title":"Cell"},{"key":"2494_CR21","doi-asserted-by":"publisher","unstructured":"Conos, S. A. et al. Active MLKL triggers the NLRP3 inflammasome in a cell-intrinsic manner. Proc. Natl Acad. Sci. USA https:\/\/doi.org\/10.1073\/pnas.1613305114 (2017).","DOI":"10.1073\/pnas.1613305114"},{"key":"2494_CR22","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/ng.3304","volume":"47","author":"JC Taylor","year":"2015","unstructured":"Taylor, J. C. et al. Factors influencing success of clinical genome sequencing across a broad spectrum of disorders. Nat. Genet. 47, 717\u2013726 (2015).","journal-title":"Nat. Genet."},{"key":"2494_CR23","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.ajhg.2008.10.010","volume":"83","author":"S Edvardson","year":"2008","unstructured":"Edvardson, S. et al. Mutations in the fatty acid 2-hydroxylase gene are associated with leukodystrophy with spastic paraparesis and dystonia. Am. J. Hum. Genet. 83, 643\u2013648 (2008).","journal-title":"Am. J. Hum. Genet."},{"key":"2494_CR24","doi-asserted-by":"publisher","first-page":"E1251","DOI":"10.1002\/humu.21205","volume":"31","author":"KJ Dick","year":"2010","unstructured":"Dick, K. J. et al. Mutation of FA2H underlies a complicated form of hereditary spastic paraplegia (SPG35). Hum. Mutat. 31, E1251\u2013E1260 (2010).","journal-title":"Hum. Mutat."},{"key":"2494_CR25","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/cge.12185","volume":"85","author":"S Donkervoort","year":"2014","unstructured":"Donkervoort, S. et al. Phenotypic variability of a likely FA2H founder mutation in a family with complicated hereditary spastic paraplegia. Clin. Genet. 85, 393\u2013395 (2014).","journal-title":"Clin. Genet."},{"key":"2494_CR26","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/cge.12336","volume":"87","author":"X Liao","year":"2015","unstructured":"Liao, X. et al. SPG35 contributes to the second common subtype of AR-HSP in China: frequency analysis and functional characterization of FA2H gene mutations. Clin. Genet. 87, 85\u201389 (2015).","journal-title":"Clin. Genet."},{"key":"2494_CR27","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/ana.22122","volume":"68","author":"MC Kruer","year":"2010","unstructured":"Kruer, M. C. et al. Defective FA2H leads to a novel form of neurodegeneration with brain iron accumulation (NBIA). Ann. Neurol. 68, 611\u2013618 (2010).","journal-title":"Ann. Neurol."},{"key":"2494_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1684-0","volume":"10","author":"ACY Lee","year":"2019","unstructured":"Lee, A. C. Y. et al. H7N9 influenza A virus activation of necroptosis in human monocytes links innate and adaptive immune responses. Cell Death Dis. 10, 442, https:\/\/doi.org\/10.1038\/s41419-019-1684-0 (2019).","journal-title":"Cell Death Dis."},{"key":"2494_CR29","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1083\/jcb.201810014","volume":"218","author":"K Sai","year":"2019","unstructured":"Sai, K., Parsons, C., House, J. S., Kathariou, S. & Ninomiya-Tsuji, J. Necroptosis mediators RIPK3 and MLKL suppress intracellular Listeria replication independently of host cell killing. J. Cell Biol. 218, 1994\u20132005 (2019).","journal-title":"J. Cell Biol."},{"key":"2494_CR30","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nmeth0410-248","volume":"7","author":"IA Adzhubei","year":"2010","unstructured":"Adzhubei, I. A. et al. A method and server for predicting damaging missense mutations. Nat. Methods 7, 248\u2013249 (2010).","journal-title":"Nat. Methods"},{"key":"2494_CR31","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1101\/gr.097857.109","volume":"20","author":"KS Pollard","year":"2010","unstructured":"Pollard, K. S., Hubisz, M. J., Rosenbloom, K. R. & Siepel, A. Detection of nonneutral substitution rates on mammalian phylogenies. Genome Res. 20, 110\u2013121 (2010).","journal-title":"Genome Res."},{"key":"2494_CR32","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nmeth.2890","volume":"11","author":"JM Schwarz","year":"2014","unstructured":"Schwarz, J. M., Cooper, D. N., Schuelke, M. & Seelow, D. MutationTaster2: mutation prediction for the deep-sequencing age. Nat. Methods 11, 361\u2013362 (2014).","journal-title":"Nat. Methods"},{"key":"2494_CR33","doi-asserted-by":"publisher","first-page":"e46688","DOI":"10.1371\/journal.pone.0046688","volume":"7","author":"Y Choi","year":"2012","unstructured":"Choi, Y., Sims, G. E., Murphy, S., Miller, J. R. & Chan, A. P. Predicting the functional effect of amino acid substitutions and indels. PLoS ONE 7, e46688 (2012).","journal-title":"PLoS ONE"},{"key":"2494_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-62703-487-6_1","volume":"1033","author":"C Ozbalci","year":"2013","unstructured":"Ozbalci, C., Sachsenheimer, T. & Brugger, B. Quantitative analysis of cellular lipids by nano-electrospray ionization mass spectrometry. Methods Mol. Biol. 1033, 3\u201320 (2013).","journal-title":"Methods Mol. Biol."},{"key":"2494_CR35","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson, A. J. et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 17, 162\u2013173 (2018).","journal-title":"Lancet Neurol."},{"key":"2494_CR36","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405\u2013424 (2015).","journal-title":"Genet. Med."},{"key":"2494_CR37","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ejmg.2011.12.001","volume":"55","author":"L Ballarati","year":"2012","unstructured":"Ballarati, L. et al. Deletion of the AP1S2 gene in a child with psychomotor delay and hypotonia. Eur. J. Med. Genet. 55, 124\u2013127 (2012).","journal-title":"Eur. J. Med. Genet."},{"key":"2494_CR38","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/ejhg.2013.135","volume":"22","author":"P Cacciagli","year":"2014","unstructured":"Cacciagli, P. et al. AP1S2 is mutated in X-linked Dandy-Walker malformation with intellectual disability, basal ganglia disease and seizures (Pettigrew syndrome). Eur. J. Hum. Genet. 22, 363\u2013368 (2014).","journal-title":"Eur. J. Hum. Genet."},{"key":"2494_CR39","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/(SICI)1096-8628(19990730)85:3<266::AID-AJMG16>3.0.CO;2-P","volume":"85","author":"NJ Carpenter","year":"1999","unstructured":"Carpenter, N. J., Brown, W. T., Qu, Y. & Keenan, K. L. Regional localization of a nonspecific X-linked mental retardation gene (MRX59) to Xp21.2-p22.2. Am. J. Med. Genet. 85, 266\u2013270 (1999).","journal-title":"Am. J. Med. Genet."},{"key":"2494_CR40","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1136\/jmg.2007.051334","volume":"44","author":"Y Saillour","year":"2007","unstructured":"Saillour, Y. et al. Mutations in the AP1S2 gene encoding the sigma 2 subunit of the adaptor protein 1 complex are associated with syndromic X-linked mental retardation with hydrocephalus and calcifications in basal ganglia. J. Med. Genet. 44, 739\u2013744 (2007).","journal-title":"J. Med. Genet."},{"key":"2494_CR41","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1086\/510137","volume":"79","author":"PS Tarpey","year":"2006","unstructured":"Tarpey, P. S. et al. Mutations in the gene encoding the Sigma 2 subunit of the adaptor protein 1 complex, AP1S2, cause X-linked mental retardation. Am. J. Hum. Genet. 79, 1119\u20131124 (2006).","journal-title":"Am. J. Hum. Genet."},{"key":"2494_CR42","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/ajmg.a.10005","volume":"117A","author":"G Turner","year":"2003","unstructured":"Turner, G. et al. Syndromic form of X-linked mental retardation with marked hypotonia in early life, severe mental handicap, and difficult adult behavior maps to Xp22. Am. J. Med. Genet. A 117A, 245\u2013250 (2003).","journal-title":"Am. J. Med. Genet. A"},{"key":"2494_CR43","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/nature19057","volume":"536","author":"M Lek","year":"2016","unstructured":"Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285\u2013291 (2016).","journal-title":"Nature"},{"key":"2494_CR44","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.molcel.2016.01.011","volume":"61","author":"G Quarato","year":"2016","unstructured":"Quarato, G. et al. Sequential engagement of distinct MLKL phosphatidylinositol-binding sites executes necroptosis. Mol. Cell 61, 589\u2013601 (2016).","journal-title":"Mol. Cell"},{"key":"2494_CR45","doi-asserted-by":"publisher","first-page":"4346","DOI":"10.1172\/JCI87545","volume":"126","author":"C Gunther","year":"2016","unstructured":"Gunther, C. et al. The pseudokinase MLKL mediates programmed hepatocellular necrosis independently of RIPK3 during hepatitis. J. Clin. Invest. 126, 4346\u20134360 (2016).","journal-title":"J. Clin. Invest."},{"key":"2494_CR46","doi-asserted-by":"publisher","unstructured":"Cekay, M. J. et al. Smac mimetics and type II interferon synergistically induce necroptosis in various cancer cell lines. Cancer Lett. https:\/\/doi.org\/10.1016\/j.canlet.2017.09.002 (2017).","DOI":"10.1016\/j.canlet.2017.09.002"},{"key":"2494_CR47","doi-asserted-by":"publisher","first-page":"E3109","DOI":"10.1073\/pnas.1301218110","volume":"110","author":"RJ Thapa","year":"2013","unstructured":"Thapa, R. J. et al. Interferon-induced RIP1\/RIP3-mediated necrosis requires PKR and is licensed by FADD and caspases. Proc. Natl Acad. Sci. USA 110, E3109\u2013E3118 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2494_CR48","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nrm4063","volume":"16","author":"S Lykke-Andersen","year":"2015","unstructured":"Lykke-Andersen, S. & Jensen, T. H. Nonsense-mediated mRNA decay: an intricate machinery that shapes transcriptomes. Nat. Rev. Mol. Cell Biol. 16, 665\u2013677 (2015).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2494_CR49","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/cr.2013.91","volume":"23","author":"J Wu","year":"2013","unstructured":"Wu, J. et al. Mlkl knockout mice demonstrate the indispensable role of Mlkl in necroptosis. Cell Res. 23, 994\u20131006 (2013).","journal-title":"Cell Res."},{"key":"2494_CR50","doi-asserted-by":"publisher","unstructured":"Markovinovic, A. et al. Optineurin in amyotrophic lateral sclerosis: multifunctional adaptor protein at the crossroads of different neuroprotective mechanisms. Prog. Neurobiol. https:\/\/doi.org\/10.1016\/j.pneurobio.2017.04.005 (2017).","DOI":"10.1016\/j.pneurobio.2017.04.005"},{"key":"2494_CR51","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/nn.4000","volume":"18","author":"A Freischmidt","year":"2015","unstructured":"Freischmidt, A. et al. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat. Neurosci. 18, 631\u2013636 (2015).","journal-title":"Nat. Neurosci."},{"key":"2494_CR52","doi-asserted-by":"publisher","first-page":"160 e161","DOI":"10.1016\/j.neurobiolaging.2018.03.006","volume":"68","author":"B Wang","year":"2018","unstructured":"Wang, B. et al. A rare variant in MLKL confers susceptibility to ApoE varepsilon4-negative Alzheimer\u2019s disease in Hong Kong Chinese population. Neurobiol. Aging 68, 160 e161\u2013160 e167 (2018).","journal-title":"Neurobiol. Aging"},{"key":"2494_CR53","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/nature11307","volume":"488","author":"AP Gregory","year":"2012","unstructured":"Gregory, A. P. et al. TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature 488, 508\u2013511 (2012).","journal-title":"Nature"},{"key":"2494_CR54","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1212\/WNL.47.6.1531","volume":"47","author":"BW van Oosten","year":"1996","unstructured":"van Oosten, B. W. et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 47, 1531\u20131534 (1996).","journal-title":"Neurology"},{"key":"2494_CR55","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1212\/WNL.53.3.457","volume":"53","author":"TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study.","year":"1999","unstructured":"TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS\/MRI Analysis Group. Neurology 53, 457\u2013465 (1999).","journal-title":"Neurology"},{"key":"2494_CR56","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.molcel.2018.09.011","volume":"72","author":"Z Ying","year":"2018","unstructured":"Ying, Z. et al. Mixed lineage kinase domain-like protein MLKL breaks down myelin following nerve injury. Mol. Cell 72, 457\u2013468 e455 (2018).","journal-title":"Mol. Cell"},{"key":"2494_CR57","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.chembiol.2019.03.010","volume":"26","author":"DE McNamara","year":"2019","unstructured":"McNamara, D. E. et al. Direct activation of human MLKL by a select repertoire of inositol phosphate metabolites. Cell Chem. Biol. 26, 863\u2013877 e867 (2019).","journal-title":"Cell Chem. Biol."},{"key":"2494_CR58","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban, X. et al. Ocrelizumab versus Placebo in primary progressive multiple sclerosis. N. Engl. J. Med. 376, 209\u2013220 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2494_CR59","doi-asserted-by":"publisher","first-page":"3637","DOI":"10.1039\/C7CC00667E","volume":"53","author":"B Yan","year":"2017","unstructured":"Yan, B. et al. Discovery of a new class of highly potent necroptosis inhibitors targeting the mixed lineage kinase domain-like protein. Chem. Commun. 53, 3637\u20133640 (2017).","journal-title":"Chem. Commun."},{"key":"2494_CR60","doi-asserted-by":"publisher","first-page":"e1600224","DOI":"10.1126\/sciadv.1600224","volume":"2","author":"D Karunakaran","year":"2016","unstructured":"Karunakaran, D. et al. Targeting macrophage necroptosis for therapeutic and diagnostic interventions in atherosclerosis. Sci. Adv. 2, e1600224 (2016).","journal-title":"Sci. Adv."},{"key":"2494_CR61","doi-asserted-by":"publisher","unstructured":"Coornaert, I. et al. Novel drug discovery strategies for atherosclerosis that target necrosis and necroptosis. Expert Opin. Drug Discov, 1\u201312, https:\/\/doi.org\/10.1080\/17460441.2018.1457644 (2018).","DOI":"10.1080\/17460441.2018.1457644"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-2494-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-2494-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-2494-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T09:48:44Z","timestamp":1670233724000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-2494-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,1]]},"references-count":61,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5]]}},"alternative-id":["2494"],"URL":"https:\/\/doi.org\/10.1038\/s41419-020-2494-0","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.737865660.793581135","asserted-by":"object"}]},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,1]]},"assertion":[{"value":"5 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.B.O. has served on scientific advisory boards for Biogen Idec, Novartis and Sanofi Genzyme; has received research support from Novartis and Biogen Idec; has received speaker honoraria from Biogen Idec, Novartis and TEVA; and has received support for congress participation from, Merck, TEVA, Biogen, Roche, Novartis and Sanofi Genzyme. P.M.M. acknowledges consultancy fees from Adelphi Communications, Biogen, Celgene and Roche; honoraria or speakers\u2019 honoraria from Biogen, Novartis and Roche; research or educational funds from Biogen, GlaxoSmithKline, Nodthera and Novartis; and he is a paid member of the scientific advisory board for Ipsen Pharmaceuticals. None of the companies had any influence over the current work. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"303"}}